Table 4.
Outcomes by 48/72 Hours Δ in NT‐proBNP
| Clinical Outcome | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| OR for Increase/Decrease of 1000 pg/mL in NT‐proBNP (95% CI) | P Value | OR for Increase/Decrease of 1000 pg/mL in NT‐proBNP (95% CI) | P Value | |
| Short‐term outcomes | ||||
| 30‐d death or HF‐rehosp.a | ||||
| Δ NT‐proBNP ≤0 | 0.90 (0.84, 0.97) | 0.007 | 0.95 (0.88, 1.02) | 0.14 |
| Δ NT‐proBNP >0 | 0.97 (0.86, 1.10) | 0.65 | 0.99 (0.87, 1.12) | 0.86 |
| 30‐d death or all‐cause‐rehosp.a | ||||
| Δ NT‐proBNP ≤0 | 0.92 (0.86, 0.97) | 0.005 | 0.95 (0.90, 1.01) | 0.13 |
| Δ NT‐proBNP >0 | 0.97 (0.88, 1.08) | 0.64 | 0.98 (0.88, 1.10) | 0.76 |
| Worsening renal functionb | ||||
| Δ NT‐proBNP ≤0 | 1.04 (0.96, 1.13) | 0.38 | 1.04 (0.62, 1.14) | 0.35 |
| Δ NT‐proBNP >0 | 1.05 (0.87, 1.27) | 0.63 | 1.06 (0.88, 1.28) | 0.54 |
| Long‐term outcomes | HR for increase/decrease of 1000 pg/mL in NT‐proBNP (95% CI) | P Value | HR for increase/decrease of 1000 pg/mL in NT‐proBNP (95% CI) | P Value |
|---|---|---|---|---|
| 180‐d deatha | ||||
| Δ NT‐proBNP ≤0 | 0.93 (0.87, 0.98) | 0.01 | 0.94 (0.88, 1.00) | 0.04 |
| Δ NT‐proBNP >0 | 0.99 (0.92, 1.06) | 0.76 | 0.95 (0.87, 1.03) | 0.20 |
Analyses adjusted for prespecified variables found to be correlated with outcomes. All models include baseline NT‐proBNP as a covariate. Hazard ratio (HR) and odds ratio (OR) estimate the change in risk associated with an increase/decrease of 1000 pg/mL from the baseline value. The relationship between ΔNT‐proBNP at 48 to 72 hours is nonlinear. Regression used piece‐wise linear splines with knot at ΔNT‐proBNP=0. Thus, the linear relationship between delta NT‐proBNP and clinical outcomes is modeled for patients with a decreased or no change in NT‐proBNP (Δ NT‐proBNP ≤0) and those with increased NT‐proBNP (Δ NT‐proBNP >0) separately in the model. CI indicates confidence interval; HF, heart failure; NT‐proBNP, N‐terminal‐pro‐b‐type natriuretic peptide; rehosp., rehospitalization.
Adjusted for region (North America or other), age, blood urea nitrogen (BUN), serum creatinine, serum sodium, chronic obstructive pulmonary disease, cerebrovascular disease, depression, dyspnea, systolic blood pressure, elevated jugular venous pulsation at baseline, randomized treatment assignment, and HF hospitalization within 1 year.
Adjusted for randomized treatment assignment, BUN, systolic and diastolic blood pressures, and weight gain.